Objective: The Acromegaly Consensus Group met in April 2009 to revisit the guidelines on
criteria for cure as defined in 2000. Participants: Participants included 74 neurosurgeons …

Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting
pituitary adenoma and leads to acromegaly—a disorder of disproportionate skeletal, tissue …

In February 1999, a workshop was held in Cortina, Italy to develop a consensus defining the
criteria for cure of acromegaly. The workshop was sponsored by the University of Brescia …

AACE= American Association of Clinical Endocrinologists; BEL=“best evidence” level;
BMD= bone mineral density; CPAP= continuous positive airway pressure; CPG= clinical …

To study the currently available data of recurrence rates of functioning and nonfunctioning
pituitary adenomas following surgical cure and to analyze associated predisposing factors …

Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant
treatment after surgery. First-line treatment with these drugs is generally used in the patients …

Acromegaly is caused by excess growth hormone (GH) secretion emanating from a
somatotroph adenoma. High GH and Insulin-like growth factor-1 (IGF-1) levels lead to acral …

The results of transsphenoidal surgery as initial therapy for GH-secreting pituitary adenomas
in 57 acromegalic patients were analyzed retrospectively. Patients with prior surgery or …

IGF-I is a multipotent growth factor with important actions on normal tissue growth and
regeneration. In addition, IGF-I has been suggested to have beneficial effects on glucose …

Increased mortality in patients with acromegaly has been confirmed in a number of
retrospective studies, but causative factors and relationship to serum IGF-I remain uncertain …